Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-384 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABT-384 Dose 1 | EXPERIMENTAL | - |
| ABT-384 Dose 2 | EXPERIMENTAL | - |
| donepezil | ACTIVE_COMPARATOR | - |
| placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABT-384 | DRUG | Subjects will take study drug once daily for 12 weeks |
| donepezil | DRUG | Subjects will take study drug once daily for 12 weeks. |
| placebo | DRUG | Subjects will take study drug once daily for 12 weeks |
Inclusion Criteria: 1. The subject and caregiver must voluntarily sign and date and informed consent. If the subject is not fully competent, full informed consent must be obtained from a legal representative and assent must be obtained from the subject. 2. Subject is male or female between the ages...
Top 20 of 24 competitors
ABT-384 is an investigational small molecule being developed for the treatment of Alzheimer's disease. It is currently in Phase 2 clinical development and has been studied in patients with mild-to-moderate Alzheimer's disease.
ABT-384 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV.
ABT-384 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed.
ABT-384 has been studied in a Phase 2 clinical trial with the identifier NCT01137526. This trial was a randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of ABT-384 in subjects with mild-to-moderate Alzheimer's disease. The trial enrolled 267 participants and has been completed.
The mechanism of action of ABT-384 has not been disclosed. It is a small molecule being investigated for its potential effects in Alzheimer's disease, but its specific molecular target is not publicly available.